Diagnosis and management of epithelial ovarian cancer

Obstetrics and Gynecology

Volumn 107, Issue 6, 2006, Pages 1399-1410

  Bhoola, Snehal ^a   Hoskins, William J ^a  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; EPITHELIUM TUMOR; HEARING LOSS; HUMAN; META ANALYSIS; NEUTROPENIA; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SYSTEMATIC REVIEW; TINNITUS; UNITED STATES; ADJUVANT THERAPY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; OVARY TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 33745602539     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000220516.34053.48     Document Type: Review

References (80)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer Statistics, 2005 [published erratum appears in CA Cancer J Clin. 2005 Jul-Aug;55(4):259]. CA Cancer J Clin 2005;55:10-30.
2. Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of Surveillance, Epidemiology, and End Results Program data. Am J Obstet Gynecol 1986;154:639-47.
3. Leitao MM, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 2004;28:147-59.
4. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003;90:378-81.
5. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004;93:301-6.
6. Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 1998;25:255-64.
7. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984;11:209-26.
8. The reduction in risk of ovarian cancer associated with oral contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
9. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1989;18:538-45.
10. Cramer DW, Hutchinson GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 1982;307:1047-51.
11. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Young RC, Markman M, Perez CA, Barakat R, Randall M, editors. Principles and practice of gynecologic oncology. 4th ed. Philadelphia (PA): Lippincott, Williams and Wilkins; 2005. p. 895-988.
12. Frank TS. Testing for hereditary risk of ovarian cancer. Cancer Control 1999;6:327-34.
13. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology 1998;12:399-406.
14. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRACA1. N Engl J Med 1996;335:1413-6.
15. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997;64:196-206.
16. Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995;17:33-5.
17. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
18. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
19. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, et al. Fallopian Tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-7.
20. Moore DH. Primary surgical management of early epithelial ovarian carcinoma. In: Rubin SC, Sutton GP, editors. Ovarian cancer. New York (NY): McGraw-Hill;1993. p. 219-40.
21. Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986;155:315-9.
22. Wu PC, Lang JH, Huang RL, Qu JY, Wang H, Tang MY, et al. Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer. Baillieres Clin Obstet Gynaecol 1986;3:143-55.
23. Jacobs IJ, Bast RC. The CA-125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.
24. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC, Jr, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14-18.
25. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989;299:1363-7.
26. van Nagell JR, Jr, Higgins RV, Donaldson ES, Gallion HH, Powell DE, Pavlik EJ, et al. Transvaginal sonography as a screening method for ovarian cancer: a report of the first 1000 cases screened. Cancer 1990;65:573-7.
27. Buys SS, Partridge E, Green MH, Prorok PC, Reding D, Riley TL, et al. Ovarian Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PCLO) cancer screening trial: findings from the initial screen of a randomized trial [published erratum appears in Am J Obstet Gynecol 2005;193:2183-4]. Am J Obstet Gynecol 2005;193:1630-9.
28. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
29. Webb MJ, Decker DG, Mussey E, Williams TJ. Factor influencing survival in Stage I ovarian cancer. Am J Obstet Gynecol 1973;116:222-8.
30. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75:263-73.
31. Trimbos JB, Schueler JA, van der Burg M, Hermans J, van Lent M, Heintz AP, et al. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 1991;67:597-602.
32. Sevelda P, Vavra N, Schemper M, Salzer H. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 1990;65:2349-52.
33. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176-82.
34. McGowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet Gynecol 1985;65:568-72.
35. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-6.
36. Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995;6:887-93.
37. Bell J, Brady M, Lage J, et al. A Randomized Phase III Trial of Carboplatin (AUC 7.5) and Paclitaxel 175mg/m2 q 21 days x 3 Courses Versus the Same Regimen x 6 Courses, in Patients with Selected Stage IC and II (A, B, C) and Selected IA and IB Ovarian Cancer. The Annual Meeting on Women's Cancer (SGO). New Orleans, LA. (2003)
38. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
39. Vogl SE, Pagano M, Kaplan BH, Greenwald E, Arseneau J, Bennett B. Cis-platin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumor burdens. Cancer 1983;51:2024-30.
40. Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 1984;18:293-8.
41. Conte PF, Sertoli MR, Bruzzone M, Rubagotti A, Rosso R, Bentivoglio G, et al. Cisplatin, methorexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. Gynecol Oncol 1985;5:290 -7.
42. Posoda Jr, JG Marantz AB, Yeung KY, Smith FP, Delgado G, Edwards BK, et al. The cyclophosphamide, hexamethymelamine, 5-fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol 1985;20:23-31.
43. Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB. Prognostic factors in advanced ovarian carcinoma. J Clinc Oncol 1986;4:515-23.
44. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, et al. Long-term survival in ovarian cancer: mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367-72.
45. Hainsworth JD, Grosh WW, Burnett LS, Jones HW, 3rd, Wolff SN, Greco FA. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988;108:165-70.
46. Piver MS, Lele SB, Marchetti DL, Baker TR, Emrich LJ, Hartman AB. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 1988;6:1679-84.
47. Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989;7:223-9.
48. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990;38:203-9.
49. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian caner. Gynecol Oncol 1992;47:203-9.
50. Michel G, De Iaco P, Castaigne D, el-Hassan MJ, Lobreglio R, Lhomme C, Rey A, Duvillard P. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1997;18:9-15.
51. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995;16:349-56.
52. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
53. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64:4-8.
54. Munkarah AR, Hallum AV 3rd, Morris M, Burke TW, Levenback C, Atkinson EN, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-7.
55. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278-87.
56. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9-12.
57. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001;82:489-97.
58. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
59. Eisenkop SM, Nalick RH, Wang HJ, Teng NN. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993;51:224-9.
60. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997;67:208-14.
61. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974-9; discussion 979-80.
62. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-8.
63. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-34.
64. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-97.
65. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88:9-16.
66. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001;92:2585-91.
67. Williams CJ, Mead GM, Macbeth FR, Thompson J, Whitehouse JM, MacDonald H, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol 1985;3:1455-62.
68. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725-30.
69. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594-600.
70. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ 1991;303, 884-93.
71. Williams CJ, Stewart L, Parmar M, Guthrie D. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. Semin Oncol 1992;19:120-8.
72. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
73. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
74. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.
75. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
76. Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56:291-6.
77. Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001;72:55-60.
78. Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000;76:157-62.
79. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
80. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.